Omeros reports positive data for rare blood disorder candidate
Hailshadow
- Shares of Omeros Corporation (NASDAQ:OMER) spiked in early trading Tuesday after announcing Phase 1 results for OMS906, its candidate for patients with rare hematological disease paroxysmal nocturnal hemoglobinuria (PNH).
- Citing an interim analysis from its ongoing Phase 1b trial, Omeros (OMER) said that OMS906 led to statistically significant and clinically meaningful improvements in PNH patients for all markers it considered for hemolysis, including hemoglobin (Hgb) and lactate dehydrogenase (LDH).
- The single-arm, open-label trial had so far enrolled nine PNH patients who received once-monthly subcutaneous administration of OMS906. All patients were complement-inhibitor-treatment naïve and received only the lowest subcutaneous dose of OMS906.
- According to the company, the experimental therapy was well tolerated generating safety data in line with Phase 1 safety observations.
- Read why Seeking Alpha analyst BiotechValley Insights reaffirmed their Strong Buy rating on OMER.